FILING ANALYSIS · MONDAY, NOVEMBER 9
Maze Therapeutics, Inc. MAZE — 8-K: Results of Operations and Financial Condition
neutral
Maze Therapeutics reported a strong balance sheet with $477 million in cash and provided updates on its clinical trials, including the completion of enrollment in the Phase 2 HORIZON trial of MZE829, but did not disclose any quantified surprises or significant changes to guidance.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →